Physician profile
Colin Vale
NPI 1982082467
$5,092.51
in general payments reported to CMS, 2019-2025
11 companies · $4,758 in 2025
The $4,758 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.19 · 2024: $311 · 2025: $4,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,780 · Travel and Lodging: $1,544 · Food and Beverage: $677 · Education: $68.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,780.00 |
| Travel and Lodging | $1,544.06 |
| Food and Beverage | $676.76 |
| Education | $68.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $4,535.22 | 2025 | Revuforj |
| Sanofi-Aventis U.S. LLC | $144.45 | 2024 | |
| Genzyme Corporation | $100.12 | 2025 | |
| Adaptive Biotechnologies Corporation | $98.26 | 2025 | Clonoseq |
| Sobi, INC | $84.32 | 2024 | |
| Astellas Pharma US INC | $68.50 | 2024 | Xospata |
| Autolus INC | $24.50 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.19 | 2021 | |
| Kite Pharma, INC. | $13.95 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Vale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.